Diabetes mellitus risk in rheumatoid arthritis: Reduced incidence with anti–tumor necrosis factor α therapy
Authors:
Open Access
- 3 October 2011
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 64 (2) , 215-221
Abstract
Objective: To examine the association of tumor necrosis factor α (TNFα) inhibitor use and the risk of developing diabetes mellitus in a rheumatoid arthritis (RA) inception cohort.Methods: Adults diagnosed with RA between January 1, 2001, and December 31, 2009, were identified (n = 1,881). Prevalent cases of diabetes mellitus (n = 294) were excluded. Information on sociodemographic data, medical history, body mass index (BMI), laboratory measures, and medications was collected from the electronic health record. Incident diabetes mellitus was defined using the 2010 American Diabetes Association criteria or physician‐established diagnosis. Time‐varying Cox proportional hazards regression models were used to adjust for age, sex, race, BMI, rheumatoid factor (RF) and anti–cyclic citrullinated peptide antibodies (anti‐CCP), erythrocyte sedimentation rate (ESR), and use of nonsteroidal antiinflammatory drugs (NSAIDs), glucocorticoids, hydroxychloroquine, and methotrexate.Results: A total of 1,587 incident RA patients without diabetes mellitus were included. The anti‐TNFα users (n = 522) had a lower median age but greater baseline BMI; maximum ESR, RF, and anti‐CCP positivity; and NSAID, glucocorticoid, or methotrexate use. The median followup time for the ever and never TNFα inhibitor users was 44.9 months (interquartile range [IQR] 23.7–73.0 months) and 37.1 months (IQR 16.3–65.1 months), respectively (P < 0.001). Of the 91 patients developing diabetes mellitus, 16 were ever and 75 were never TNFα inhibitor users, yielding incidence rates of 8.6 and 17.2 per 1,000 person‐years (P = 0.048), respectively. Adjusting for covariates, the hazard ratio for incident diabetes mellitus in TNFα inhibitor users was 0.49 (95% confidence interval 0.24–0.99, P = 0.049) compared to the never users.Conclusion: In this inception RA cohort, anti‐TNFα use was associated with a 51% reduction in risk of developing diabetes mellitus.Keywords
This publication has 30 references indexed in Scilit:
- Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severityAnnals of the Rheumatic Diseases, 2010
- Abnormal body composition phenotypes in older rheumatoid arthritis patients: Association with disease characteristics and pharmacotherapiesArthritis Care & Research, 2008
- Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitusAnnals of the Rheumatic Diseases, 2007
- Effects of etanercept or infliximab treatment on lipid profile and insulin resistance in patients with refractory rheumatoid arthritisClinical Rheumatology, 2007
- Improved insulin sensitivity by anti-TNFα antibody treatment in patients with rheumatic diseasesAnnals of the Rheumatic Diseases, 2007
- Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritisClinical Rheumatology, 2007
- Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitisAnnals of the Rheumatic Diseases, 2005
- Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha.Journal of Clinical Investigation, 1994
- Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin ResistanceScience, 1993
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988